Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Faster Finish May Depend On A Better Start – EMA's PRIME Program

This article was originally published in The Pink Sheet Daily

Executive Summary

EMA officials spotlight need to improve clinical development plans in the early stages, with agency exec director Rasi saying many trials are "useless." They shy away from predicting timelines or goals for quicker reviews.

You may also be interested in...



European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes

Once-in-a-decade leadership changes stack up in Europe’s big pharma companies as the region aims for quicker and more certain drug development, although following a recent fatality an expert committee is advising caution during dose-escalation in Phase I studies.

PRIME Time: Smaller Companies In Focus As EMA Launches Priority Medicines Scheme

In exceptional cases, smaller and medium-sized companies might obtain PRIME designation in proof of principle stage, underscoring the expectation that they will particularly benefit from the program.

PRIME Time: Smaller Companies In Focus As EMA Launches Priority Medicines Scheme

In exceptional cases, smaller and medium-sized companies might obtain PRIME designation in proof of principle stage, underscoring the expectation that they will particularly benefit from the program.

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel